New strategies for the treatment of hormone-independent prostate cancer

Journal of B.U.ON.

Volumn 7, Issue 2, 2002, Pages 107-112

  Bogdanos, Ioannis ^a   Karamanolakis, D ^a   Milathianakis, C ^a   Tsintavis, A ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Hormone refractory; New stragies; Prostate cancer; Treatment

Indexed keywords

ANDROGEN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BAI 129566; BISPHOSPHONIC ACID DERIVATIVE; CHLORMETHINE; CYTOSTATIC AGENT; DEXAMETHASONE; DOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETOPOSIDE; GANCICLOVIR; GLUCOCORTICOID; HORMONE; HYDROCORTISONE; IMIDAZOLE; KETOCONAZOLE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PRINOMASTAT; PROTEIN TYROSINE KINASE; RADIOPHARMACEUTICAL AGENT; RECOMBINANT CYTOKINE; RHENIUM 163; STRONTIUM 89; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VANCICLOVIR; VINBLASTINE;

ADRENAL INSUFFICIENCY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FOOD DRUG INTERACTION; GENE THERAPY; HUMAN; MALE; NEUTROPENIA; NONHUMAN; PROCTITIS; PROSTATE CANCER; REVIEW; STOMATITIS; TREATMENT FAILURE; UNITED STATES;

EID: 0036315501     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Studies on prostate cancer: I. The effect of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
2. Endocrine control of prostatic carcinoma
3. Response criteria of the prostate of the USA National Prostatic Cancer Project
4. Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies
5. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation
6. The flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostatic cancer
7. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system
8. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
9. Second-line hormonal therapy for advanced prostate cancer. A shifting paradigm
10. Supportive care in the patient with hormone refractory prostate cancer
11. Use of dexamethasone for ureteric obstruction in advanced prostate cancer: Percutaneous nephrostomies can be avoided
12. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
13. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
14. Biphosphonates in prostate cancer
15. The effects of pamidronate disodium treatment in metastatic prostate cancer
16. Palliation of bone pain by the biphosphonate olpadronate in hormone escaped prostate adenocarcinoma metastatic to the skeleton
17. Estramustine phosphate-historical overview
18. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
19. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer
20. Oral estramustine and oral etoposide for hormone-refractory prostate cancer
21. Mitoxantrone: Modest activity in a phase II trial in advanced prostate cancer
22. 14-day continuous infusion of mitoxantrone in hormone-refractory metastatic adenocarcinoma of the prostate
23. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
24. Estramustine depolymerizes microtubules by binding to tubulin
25. Paclitaxel (Taxol)
26. A phase II trial of oral estramustine and oral etoposide in hormone-refractory prostate cancer
27. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines
28. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
29. The experience with suramin in advanced prostate cancer
30. Metastatic epidural spinal cord compression: Results of treatment and survival
31. Bone metastases: Pathophysiology and management policy
32. Radiotherapy for regionally localized hormone-refractory prostate cancer
33. Strontium-89 treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone
34. Strontium-89 for pain palliation in prostatic skeletal malignancy
35. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer
36. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model
37. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone
38. Suicide gene therapy in prostate cancer causes tumour growth retardation and improved survival
39. Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides
40. Demonstration of a rational strategy for human prostate cancer gene therapy
41. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumours
42. Marimastat (BB 2516): Current status of development
43. Novel targets in cancer therapy: Angiogenesis, matrix metalloproteases, cycline dependent kinases and signal transductions
44. Antagonists of retinoic acid receptors (RARs) are potent growth inhibitors of prostate carcinoma cells
45. Ketokonazole and liarozole in the treatment of advanced prostate cancer
46. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
47. How much should we rely on the level of PSA for evaluation of clinical trials - A word of caution
48. Therapeutic potential of curcumin in human prostate cancer II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein
49. Novel concept of antisurvival factor (ASF) therapy produces objective clinical response in four patients with hormone-refractory prostate cancer: Case report
50. New approaches to drug development in prostatic cancer
51. Prostate specific antigen in preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy
52. Prostate specific antigen: An important marker for prostate cancer treated by external beam radiation therapy
53. High dose epirubicin is effective in measurable metastatic prostate cancer: A phase II study of the EORTC Genitourinary Group
54. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer